A practical reference on lyophilised powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-28 and is reviewed periodically as new material appears.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
=== Structural domain === A structural domain is an element of the protein's overall structure that is self-stabilizing and often folds independently of the rest of the protein chain. Many domains are not unique to the protein products of one gene or one gene family but instead appear in a variety of proteins. Domains often are named and singled out because they figure prominently in the biological function of the protein they belong to; for example, the "calcium-binding domain of calmodulin". Because they are independently stable, domains can be "swapped" by genetic engineering between one protein and another to make chimera proteins. A conservative combination of several domains that occur in different proteins, such as protein tyrosine phosphatase domain and C2 domain pair, was called "a superdomain" that may evolve as a single unit.
In some cases, such as in parts of Kenya in 2006, rates of malnutrition in pregnant women were even higher than rates in children. Women in some societies are traditionally given less food than men since men are perceived to have heavier workloads. Household chores and agricultural tasks can in fact be very arduous and require additional energy and nutrients; however, physical activity, which largely determines energy requirements, is difficult to estimate.
Norman architecture typically stands out as a new stage in the architectural history of the regions they subdued. They spread a unique Romanesque idiom to England, Italy and Ireland, and the encastellation of these regions with keeps in their north French style fundamentally altered the military landscape. Their style was characterised by rounded arches, particularly over windows and doorways, and massive proportions. In England, the period of Norman architecture immediately succeeds that of the Anglo-Saxon and precedes the Early Gothic. In southern Italy, the Normans incorporated elements of Islamic, Lombard, and Byzantine building techniques into their own, initiating a unique romanesque style known as Norman-Arab architecture within the Kingdom of Sicily and precedes the Early Gothic.
== Ophthalmic acid is not a biomarker of oxidative stress == OPH has mostly appeared in metabolomics studies correlating changes in its abundance with oxidative stress, following a study from 2006 on acetaminophen overdose in mice. However, this practice should generally be avoided, as there are major issues:
Anti-metabolites are a group of molecules that impede DNA and RNA synthesis. Many of them have a similar structure to the building blocks of DNA and RNA. The building blocks are nucleotides; a molecule comprising a nucleobase, a sugar and a phosphate group. The nucleobases are divided into purines (guanine and adenine) and pyrimidines (cytosine, thymine and uracil). Anti-metabolites resemble either nucleobases or nucleosides (a nucleotide without the phosphate group), but have altered chemical groups. These drugs exert their effect by either blocking the enzymes required for DNA synthesis or becoming incorporated into DNA or RNA. By inhibiting the enzymes involved in DNA synthesis, they prevent mitosis because the DNA cannot duplicate itself. Also, after misincorporation of the molecules into DNA, DNA damage can occur and programmed cell death (apoptosis) is induced. Unlike alkylating agents, anti-metabolites are cell cycle dependent. This means that they only work during a specific part of the cell cycle, in this case S-phase (the DNA synthesis phase). For this reason, at a certain dose, the effect plateaus and proportionally no more cell death occurs with increased doses. Subtypes of the anti-metabolites are the anti-folates, fluoropyrimidines, deoxynucleoside analogues and thiopurines. The anti-folates include methotrexate and pemetrexed. Methotrexate inhibits dihydrofolate reductase (DHFR), an enzyme that regenerates tetrahydrofolate from dihydrofolate. When the enzyme is inhibited by methotrexate, the cellular levels of folate coenzymes diminish.
Sources: en.wikipedia.org
=== Modification after heptapeptide backbone formation === Once the heptapeptide backbone has been formed, the linear enzyme-bound intermediate is cyclized. Gene disruption studies indicate cytochrome P450 oxygenases as the enzymes that performs the coupling reactions. The X-domain in the final NRPS module is required to recruit the oxygenase enzymes. OxyB forms the first ring by coupling residues 4 and 6, and OxyE then couples residues 1 and 3. OxyA couples residues 2 and 4, followed by the formation of a C-C bond between residues 5 and 7 by OxyC. The regioselectivity and atropisomer selectivity of these probable one-electron coupling reactions has been suggested to be due to the folding and orientation requirements of the partially crossed-linked substrates in the enzyme active site. The coupling reactions are shown below.
== Types == Popliteal pterygium syndrome, a congenital condition affecting the face, limbs, or genitalia but named after the wing-like structural anomaly behind the knee. Pterygium (eye) or surfer's eye, a growth on the cornea of the eye. Pterygium colli or webbed neck, a congenital skin fold of the neck down to the shoulders. Pterygium inversum unguis or ventral pterygium, adherence of the distal portion of the nailbed to the ventral surface of the nail plate. Pterygium unguis or dorsal pterygium, scarring between the proximal nail fold and matrix.
== History == Nefazodone was discovered by scientists at Bristol-Myers Squibb (BMS) who were seeking to improve on trazodone by reducing its sedating qualities. BMS obtained marketing approvals for nefazodone worldwide, including in the United States and Europe, in 1994. It was marketed in the United States under the brand name Serzone and in Europe under the brand name Dutonin. The first reports of serious liver toxicity with nefazodone were published in 1998 and 1999. These instances were quickly followed by many additional cases. In 2002, the United States Food and Drug Administration (FDA) obligated BMS to add a black box warning about potential fatal liver toxicity to the drug label. Worldwide sales in 2002 were $409 million. In 2003 Public Citizen filed a citizen petition asking the FDA to withdraw the marketing authorization in the United States, and in early 2004 the organization sued the FDA to attempt to force withdrawal of the drug. The FDA issued a response to the petition in June 2004 and filed a motion to dismiss, and Public Citizen withdrew the suit. Sales of nefazodone were about $100 million in 2003. By that time, it was also being marketed under the additional brand names Serzonil, Nefadar, and Rulivan. Generic versions were introduced in the United States in 2003 and Health Canada withdrew the marketing authorization that same year. In April 2004, BMS announced that it was going to discontinue the sale of Serzone in the United States in June 2004 and said that this was due to declining sales and generic versions being available in the United States.
==== Pregnancy ==== It has not been shown to cause birth defects in animal studies when given intravenously. There are no controlled studies to show if pentamidine can harm the fetus in pregnant women. It is only recommended if the drug of choice trimethoprim-sulfamethoxazole is contraindicated.
Sources: en.wikipedia.org
== Education == Longaker attended Michigan State University and Harvard Medical School. After obtaining degrees at both schools, he went on to become a resident at the University of California, San Francisco. He studied wound healing in the unborn fetus under Michael R. Harrison. At Michigan State, he was on the 1977-78, 1978-79, and 1979–80 Michigan State Spartans men's basketball team, where he played as a guard.
==== Mixed oxidant ==== A simple brine {salt + water} solution in an electrolytic reaction produces a powerful mixed oxidant disinfectant (mostly chlorine in the form of hypochlorous acid (HOCl) and some peroxide, ozone, chlorine dioxide).
== Clinical Research and Clinical Trials == Clinical research at the Barshop Institute is dedicated to translating discoveries in the biology of aging into interventions that improve healthspan, preserve functional independence, and prevent or delay the onset of chronic age-related diseases. The Institute maintains a robust clinical research infrastructure that supports Phase I–IV clinical trials, investigator-initiated studies, and multicenter collaborations spanning basic translational research through large-scale clinical investigations. Investigators conduct studies involving older adults across a broad spectrum of aging-related conditions, including frailty, sarcopenia, metabolic dysfunction, obesity, type 2 diabetes, cardiovascular disease, Alzheimer's disease and related dementias, mobility impairment, osteoporosis, and other chronic conditions that disproportionately affect aging populations. Clinical trials evaluate novel therapeutics, lifestyle interventions, nutritional strategies, exercise programs, and repurposed medications designed to improve physical function, cognitive health, metabolic resilience, and overall quality of life. The Institute's clinical research enterprise is strengthened through close collaboration among physician-scientists, basic scientists, biostatisticians, epidemiologists, rehabilitation specialists, nutrition experts, and clinical research professionals.
History of flow chemistry – history of chemical reactions run in a continuously flowing stream rather than in batch production. History of geochemistry – history of the study of the mechanisms behind major geological systems using chemistry History of aqueous geochemistry – history of the study of the role of various elements in watersheds, including copper, sulfur, mercury, and how elemental fluxes are exchanged through atmospheric-terrestrial-aquatic interactions History of isotope geochemistry – history of the study of the relative and absolute concentrations of the elements and their isotopes using chemistry and geology History of ocean chemistry – history of the study the chemistry of marine environments, including the influences of different variables. History of organic geochemistry – history of the study of the impacts and processes that organisms have had on Earth History of regional, environmental and exploration geochemistry – history of the study of the spatial variation in the chemical composition of materials at the surface of the Earth History of inorganic chemistry – history of the branch of chemistry concerned with the properties and behavior of inorganic compounds. History of nuclear chemistry – history of the subfield of chemistry dealing with radioactivity, nuclear processes and nuclear properties.
Based on the hearings, Congress authorized a budget that allowed the library to more than double its staff, from 42 to 108 persons. Senators Justin Morrill of Vermont and Daniel W. Voorhees of Indiana were particularly helpful in gaining this support. The library also established new administrative units for all aspects of the collection. In its bill, Congress strengthened the role of librarian of Congress: it became responsible for governing the library and making staff appointments. As with presidential Cabinet appointments, the Senate was required to approve presidential appointees to the position. In 1893, Elizabeth Dwyer became the first woman to be appointed to the staff of the library.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.